Celcuity Inc.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- CELCCelcuity Inc0Calm
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Signing up patientsPhase 31,180 patientsMain results: Mar 31, 2029 - CELCCelcuity Inc0Calm
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Signing up patientsPhase 1/254 patientsMain results: Jan 2028 - CELCCelcuity Inc0Calm
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Running, no new patientsPhase 3701 patientsMain results: Jun 30, 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
2 sales (2 not pre-planned) · 0 purchases
- BAKER BROS. ADVISORS LPLarge shareholder · Jul 14, 2026Sold 261,368 sharesabout $26.8 million · not pre-planned
- BAKER BROS. ADVISORS LPLarge shareholder · Jul 14, 2026Sold 2,838,632 sharesabout $291.0 million · not pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Quarterly reportQuarterly report (10-Q)Nov 5, 2026
- Shared quarterly resultsNews report (8-K)Nov 5, 2026
- An executive or board member joined or left; Shared information with investorsNews report (8-K)Oct 2, 2026
- Shared information with investors; Other newsNews report (8-K)Sep 30, 2026
- Shared information with investors; Other newsNews report (8-K)Aug 26, 2026